Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
NCT07866066
This study is recruiting at 7 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diabetes Mellitus, Type 2
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- November 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Acclaim Clinical Research · San Diego, CA
Florida · 4
- Bioclinical Research Alliance · Miami, FL
- Indago Research and Health Center · Miami Lakes, FL
- Clinical Research Center Of Florida · Pompano Beach, FL
- Conquest Research - Winter Park · Winter Park, FL
Virginia · 1
- Virginia Nephrology Group · Arlington, VA
Washington · 1
- Eastside Research Associates Health Research · Redmond, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.